Global HIV Drugs Market 2023-2027

The HIV drugs market is forecasted to grow by USD 10477.51 mn during 2022-2027, accelerating at a CAGR of 5.46% during the forecast period. The report on the HIV drugs market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.

The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment. The market is driven by increasing prevalence of HIV aids worldwide, increasing cases of associated risk factors, and surge in geriatric population.

Technavio's HIV drugs market is segmented as below:

By Distribution Channel

Offline
Online

By Therapy

Combination HIV medicines
Integrase inhibitors
Non-nucleoside reverse transcriptase inhibitors
Others

By Geographical Landscape

North America
Europe
Asia
Rest of World (ROW)

This study identifies the expanding access to HIV treatment as one of the prime reasons driving the HIV drugs market growth during the next few years. Also, rising demand for targeted therapies and advances in the diagnostics of HIV virus will lead to sizable demand in the market.

The report on the HIV drugs market covers the following areas:

HIV drugs market sizing
HIV drugs market forecast
HIV drugs market industry analysis

The robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading HIV drugs market vendors that include AbbVie Inc., Aspen Pharmacare Holdings Ltd, Aurobindo Pharma Ltd., Boehringer Ingelheim International GmbH, Bristol Myers Squibb Co., Cipla Ltd., Emcure Pharmaceuticals Ltd., Gilead Sciences Inc., GlaxoSmithKline Plc, Hetero Labs Ltd., Johnson and Johnson Services Inc., Lupin Ltd., Macleods Pharmaceuticals Ltd., Merck and Co. Inc., Strides Pharma Science Ltd., Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Ltd., Torrent Pharmaceuticals Ltd., Viatris Inc., and Cadila Pharmaceuticals Ltd.. Also, the HIV drugs market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.

The publisher presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast the accurate market growth.

Product Code: IRTNTR75747

1 Executive Summary

1.1 Market overview
Exhibit 01: Executive Summary - Chart on Market Overview
Exhibit 02: Executive Summary - Data Table on Market Overview
Exhibit 03: Executive Summary - Chart on Global Market Characteristics
Exhibit 04: Executive Summary - Chart on Market By Geographical Landscape
Exhibit 05: Executive Summary - Chart on Market Segmentation by Distribution Channel
Exhibit 06: Executive Summary - Chart on Market Segmentation by Therapy
Exhibit 07: Executive Summary - Chart on Incremental Growth
Exhibit 08: Executive Summary - Data Table on Incremental Growth
Exhibit 09: Executive Summary - Chart on Vendor Market Positioning

2 Market Landscape

2.1 Market ecosystem
Exhibit 10: Parent market
Exhibit 11: Market Characteristics

3 Market Sizing

3.1 Market definition
Exhibit 12: Offerings of vendors included in the market definition
3.2 Market segment analysis
Exhibit 13: Market segments
3.3 Market size 2022
3.4 Market outlook: Forecast for 2022-2027
Exhibit 14: Chart on Global - Market size and forecast 2022-2027 ($ million)
Exhibit 15: Data Table on Global - Market size and forecast 2022-2027 ($ million)
Exhibit 16: Chart on Global Market: Year-over-year growth 2022-2027 (%)
Exhibit 17: Data Table on Global Market: Year-over-year growth 2022-2027 (%)

4 Historic Market Size

4.1 Global HIV drugs market 2017 - 2021
Exhibit 18: Historic Market Size - Data Table on global hiv drugs market 2017 - 2021 ($ million)
4.2 Distribution Channel Segment Analysis 2017 - 2021
Exhibit 19: Historic Market Size - Distribution Channel Segment 2017 - 2021 ($ million)
4.3 Therapy Segment Analysis 2017 - 2021
Exhibit 20: Historic Market Size - Therapy Segment 2017 - 2021 ($ million)
4.4 Geography Segment Analysis 2017 - 2021
Exhibit 21: Historic Market Size - Geography Segment 2017 - 2021 ($ million)
4.5 Country Segment Analysis 2017 - 2021
Exhibit 22: Historic Market Size - Country Segment 2017 - 2021 ($ million)

5 Five Forces Analysis

5.1 Five forces summary
Exhibit 23: Five forces analysis - Comparison between 2022 and 2027
5.2 Bargaining power of buyers
Exhibit 24: Chart on Bargaining power of buyers - Impact of key factors 2022 and 2027
5.3 Bargaining power of suppliers
Exhibit 25: Bargaining power of suppliers - Impact of key factors in 2022 and 2027
5.4 Threat of new entrants
Exhibit 26: Threat of new entrants - Impact of key factors in 2022 and 2027
5.5 Threat of substitutes
Exhibit 27: Threat of substitutes - Impact of key factors in 2022 and 2027
5.6 Threat of rivalry
Exhibit 28: Threat of rivalry - Impact of key factors in 2022 and 2027
5.7 Market condition
Exhibit 29: Chart on Market condition - Five forces 2022 and 2027

6 Market Segmentation by Distribution Channel

6.1 Market segments
Exhibit 30: Chart on Distribution Channel - Market share 2022-2027 (%)
Exhibit 31: Data Table on Distribution Channel - Market share 2022-2027 (%)
6.2 Comparison by Distribution Channel
Exhibit 32: Chart on Comparison by Distribution Channel
Exhibit 33: Data Table on Comparison by Distribution Channel
6.3 Offline - Market size and forecast 2022-2027
Exhibit 34: Chart on Offline - Market size and forecast 2022-2027 ($ million)
Exhibit 35: Data Table on Offline - Market size and forecast 2022-2027 ($ million)
Exhibit 36: Chart on Offline - Year-over-year growth 2022-2027 (%)
Exhibit 37: Data Table on Offline - Year-over-year growth 2022-2027 (%)
6.4 Online - Market size and forecast 2022-2027
Exhibit 38: Chart on Online - Market size and forecast 2022-2027 ($ million)
Exhibit 39: Data Table on Online - Market size and forecast 2022-2027 ($ million)
Exhibit 40: Chart on Online - Year-over-year growth 2022-2027 (%)
Exhibit 41: Data Table on Online - Year-over-year growth 2022-2027 (%)
6.5 Market opportunity by Distribution Channel
Exhibit 42: Market opportunity by Distribution Channel ($ million)
Exhibit 43: Data Table on Market opportunity by Distribution Channel ($ million)

7 Market Segmentation by Therapy

7.1 Market segments
Exhibit 44: Chart on Therapy - Market share 2022-2027 (%)
Exhibit 45: Data Table on Therapy - Market share 2022-2027 (%)
7.2 Comparison by Therapy
Exhibit 46: Chart on Comparison by Therapy
Exhibit 47: Data Table on Comparison by Therapy
7.3 Combination HIV medicines - Market size and forecast 2022-2027
Exhibit 48: Chart on Combination HIV medicines - Market size and forecast 2022-2027 ($ million)
Exhibit 49: Data Table on Combination HIV medicines - Market size and forecast 2022-2027 ($ million)
Exhibit 50: Chart on Combination HIV medicines - Year-over-year growth 2022-2027 (%)
Exhibit 51: Data Table on Combination HIV medicines - Year-over-year growth 2022-2027 (%)
7.4 Integrase inhibitors - Market size and forecast 2022-2027
Exhibit 52: Chart on Integrase inhibitors - Market size and forecast 2022-2027 ($ million)
Exhibit 53: Data Table on Integrase inhibitors - Market size and forecast 2022-2027 ($ million)
Exhibit 54: Chart on Integrase inhibitors - Year-over-year growth 2022-2027 (%)
Exhibit 55: Data Table on Integrase inhibitors - Year-over-year growth 2022-2027 (%)
7.5 Non-nucleoside reverse transcriptase inhibitors - Market size and forecast 2022-2027
Exhibit 56: Chart on Non-nucleoside reverse transcriptase inhibitors - Market size and forecast 2022-2027 ($ million)
Exhibit 57: Data Table on Non-nucleoside reverse transcriptase inhibitors - Market size and forecast 2022-2027 ($ million)
Exhibit 58: Chart on Non-nucleoside reverse transcriptase inhibitors - Year-over-year growth 2022-2027 (%)
Exhibit 59: Data Table on Non-nucleoside reverse transcriptase inhibitors - Year-over-year growth 2022-2027 (%)
7.6 Others - Market size and forecast 2022-2027
Exhibit 60: Chart on Others - Market size and forecast 2022-2027 ($ million)
Exhibit 61: Data Table on Others - Market size and forecast 2022-2027 ($ million)
Exhibit 62: Chart on Others - Year-over-year growth 2022-2027 (%)
Exhibit 63: Data Table on Others - Year-over-year growth 2022-2027 (%)
7.7 Market opportunity by Therapy
Exhibit 64: Market opportunity by Therapy ($ million)
Exhibit 65: Data Table on Market opportunity by Therapy ($ million)

8 Customer Landscape

8.1 Customer landscape overview
Exhibit 66: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria

9 Geographic Landscape

9.1 Geographic segmentation
Exhibit 67: Chart on Market share By Geographical Landscape 2022-2027 (%)
Exhibit 68: Data Table on Market share By Geographical Landscape 2022-2027 (%)
9.2 Geographic comparison
Exhibit 69: Chart on Geographic comparison
Exhibit 70: Data Table on Geographic comparison
9.3 North America - Market size and forecast 2022-2027
Exhibit 71: Chart on North America - Market size and forecast 2022-2027 ($ million)
Exhibit 72: Data Table on North America - Market size and forecast 2022-2027 ($ million)
Exhibit 73: Chart on North America - Year-over-year growth 2022-2027 (%)
Exhibit 74: Data Table on North America - Year-over-year growth 2022-2027 (%)
9.4 Europe - Market size and forecast 2022-2027
Exhibit 75: Chart on Europe - Market size and forecast 2022-2027 ($ million)
Exhibit 76: Data Table on Europe - Market size and forecast 2022-2027 ($ million)
Exhibit 77: Chart on Europe - Year-over-year growth 2022-2027 (%)
Exhibit 78: Data Table on Europe - Year-over-year growth 2022-2027 (%)
9.5 Asia - Market size and forecast 2022-2027
Exhibit 79: Chart on Asia - Market size and forecast 2022-2027 ($ million)
Exhibit 80: Data Table on Asia - Market size and forecast 2022-2027 ($ million)
Exhibit 81: Chart on Asia - Year-over-year growth 2022-2027 (%)
Exhibit 82: Data Table on Asia - Year-over-year growth 2022-2027 (%)
9.6 Rest of World (ROW) - Market size and forecast 2022-2027
Exhibit 83: Chart on Rest of World (ROW) - Market size and forecast 2022-2027 ($ million)
Exhibit 84: Data Table on Rest of World (ROW) - Market size and forecast 2022-2027 ($ million)
Exhibit 85: Chart on Rest of World (ROW) - Year-over-year growth 2022-2027 (%)
Exhibit 86: Data Table on Rest of World (ROW) - Year-over-year growth 2022-2027 (%)
9.7 US - Market size and forecast 2022-2027
Exhibit 87: Chart on US - Market size and forecast 2022-2027 ($ million)
Exhibit 88: Data Table on US - Market size and forecast 2022-2027 ($ million)
Exhibit 89: Chart on US - Year-over-year growth 2022-2027 (%)
Exhibit 90: Data Table on US - Year-over-year growth 2022-2027 (%)
9.8 Germany - Market size and forecast 2022-2027
Exhibit 91: Chart on Germany - Market size and forecast 2022-2027 ($ million)
Exhibit 92: Data Table on Germany - Market size and forecast 2022-2027 ($ million)
Exhibit 93: Chart on Germany - Year-over-year growth 2022-2027 (%)
Exhibit 94: Data Table on Germany - Year-over-year growth 2022-2027 (%)
9.9 China - Market size and forecast 2022-2027
Exhibit 95: Chart on China - Market size and forecast 2022-2027 ($ million)
Exhibit 96: Data Table on China - Market size and forecast 2022-2027 ($ million)
Exhibit 97: Chart on China - Year-over-year growth 2022-2027 (%)
Exhibit 98: Data Table on China - Year-over-year growth 2022-2027 (%)
9.10 UK - Market size and forecast 2022-2027
Exhibit 99: Chart on UK - Market size and forecast 2022-2027 ($ million)
Exhibit 100: Data Table on UK - Market size and forecast 2022-2027 ($ million)
Exhibit 101: Chart on UK - Year-over-year growth 2022-2027 (%)
Exhibit 102: Data Table on UK - Year-over-year growth 2022-2027 (%)
9.11 Canada - Market size and forecast 2022-2027
Exhibit 103: Chart on Canada - Market size and forecast 2022-2027 ($ million)
Exhibit 104: Data Table on Canada - Market size and forecast 2022-2027 ($ million)
Exhibit 105: Chart on Canada - Year-over-year growth 2022-2027 (%)
Exhibit 106: Data Table on Canada - Year-over-year growth 2022-2027 (%)
9.12 Market opportunity By Geographical Landscape
Exhibit 107: Market opportunity By Geographical Landscape ($ million)
Exhibit 108: Data Tables on Market opportunity By Geographical Landscape ($ million)

10 Drivers, Challenges, and Trends

10.1 Market drivers
10.2 Market challenges
10.3 Impact of drivers and challenges
Exhibit 109: Impact of drivers and challenges in 2022 and 2027
10.4 Market trends

11 Vendor Landscape

11.1 Overview
11.2 Vendor landscape
Exhibit 110: Overview on Criticality of inputs and Factors of differentiation
11.3 Landscape disruption
Exhibit 111: Overview on factors of disruption
11.4 Industry risks
Exhibit 112: Impact of key risks on business

12 Vendor Analysis

12.1 Vendors covered
Exhibit 113: Vendors covered
12.2 Market positioning of vendors
Exhibit 114: Matrix on vendor position and classification
12.3 AbbVie Inc.
Exhibit 115: AbbVie Inc. - Overview
Exhibit 116: AbbVie Inc. - Product / Service
Exhibit 117: AbbVie Inc. - Key news
Exhibit 118: AbbVie Inc. - Key offerings
12.4 Aurobindo Pharma Ltd.
Exhibit 119: Aurobindo Pharma Ltd. - Overview
Exhibit 120: Aurobindo Pharma Ltd. - Product / Service
Exhibit 121: Aurobindo Pharma Ltd. - Key offerings
12.5 Bristol Myers Squibb Co.
Exhibit 122: Bristol Myers Squibb Co. - Overview
Exhibit 123: Bristol Myers Squibb Co. - Product / Service
Exhibit 124: Bristol Myers Squibb Co. - Key news
Exhibit 125: Bristol Myers Squibb Co. - Key offerings
12.6 Cadila Pharmaceuticals Ltd.
Exhibit 126: Cadila Pharmaceuticals Ltd. - Overview
Exhibit 127: Cadila Pharmaceuticals Ltd. - Product / Service
Exhibit 128: Cadila Pharmaceuticals Ltd. - Key offerings
12.7 Cipla Ltd.
Exhibit 129: Cipla Ltd. - Overview
Exhibit 130: Cipla Ltd. - Business segments
Exhibit 131: Cipla Ltd. - Key news
Exhibit 132: Cipla Ltd. - Key offerings
Exhibit 133: Cipla Ltd. - Segment focus
12.8 Emcure Pharmaceuticals Ltd.
Exhibit 134: Emcure Pharmaceuticals Ltd. - Overview
Exhibit 135: Emcure Pharmaceuticals Ltd. - Product / Service
Exhibit 136: Emcure Pharmaceuticals Ltd. - Key offerings
12.9 Gilead Sciences Inc.
Exhibit 137: Gilead Sciences Inc. - Overview
Exhibit 138: Gilead Sciences Inc. - Product / Service
Exhibit 139: Gilead Sciences Inc. - Key news
Exhibit 140: Gilead Sciences Inc. - Key offerings
12.10 GlaxoSmithKline Plc
Exhibit 141: GlaxoSmithKline Plc - Overview
Exhibit 142: GlaxoSmithKline Plc - Business segments
Exhibit 143: GlaxoSmithKline Plc - Key news
Exhibit 144: GlaxoSmithKline Plc - Key offerings
Exhibit 145: GlaxoSmithKline Plc - Segment focus
12.11 Hetero Labs Ltd.
Exhibit 146: Hetero Labs Ltd. - Overview
Exhibit 147: Hetero Labs Ltd. - Product / Service
Exhibit 148: Hetero Labs Ltd. - Key offerings
12.12 Johnson and Johnson Services Inc.
Exhibit 149: Johnson and Johnson Services Inc. - Overview
Exhibit 150: Johnson and Johnson Services Inc. - Business segments
Exhibit 151: Johnson and Johnson Services Inc. - Key news
Exhibit 152: Johnson and Johnson Services Inc. - Key offerings
Exhibit 153: Johnson and Johnson Services Inc. - Segment focus
12.13 Lupin Ltd.
Exhibit 154: Lupin Ltd. - Overview
Exhibit 155: Lupin Ltd. - Product / Service
Exhibit 156: Lupin Ltd. - Key news
Exhibit 157: Lupin Ltd. - Key offerings
12.14 Merck and Co. Inc.
Exhibit 158: Merck and Co. Inc. - Overview
Exhibit 159: Merck and Co. Inc. - Business segments
Exhibit 160: Merck and Co. Inc. - Key news
Exhibit 161: Merck and Co. Inc. - Key offerings
Exhibit 162: Merck and Co. Inc. - Segment focus
12.15 Sun Pharmaceutical Industries Ltd.
Exhibit 163: Sun Pharmaceutical Industries Ltd. - Overview
Exhibit 164: Sun Pharmaceutical Industries Ltd. - Product / Service
Exhibit 165: Sun Pharmaceutical Industries Ltd. - Key offerings
12.16 Teva Pharmaceutical Industries Ltd.
Exhibit 166: Teva Pharmaceutical Industries Ltd. - Overview
Exhibit 167: Teva Pharmaceutical Industries Ltd. - Business segments
Exhibit 168: Teva Pharmaceutical Industries Ltd. - Key news
Exhibit 169: Teva Pharmaceutical Industries Ltd. - Key offerings
Exhibit 170: Teva Pharmaceutical Industries Ltd. - Segment focus
12.17 Viatris Inc.
Exhibit 171: Viatris Inc. - Overview
Exhibit 172: Viatris Inc. - Business segments
Exhibit 173: Viatris Inc. - Key news
Exhibit 174: Viatris Inc. - Key offerings
Exhibit 175: Viatris Inc. - Segment focus

13 Appendix

13.1 Scope of the report
13.2 Inclusions and exclusions checklist
Exhibit 176: Inclusions checklist
Exhibit 177: Exclusions checklist
13.3 Currency conversion rates for US$
Exhibit 178: Currency conversion rates for US$
13.4 Research methodology
Exhibit 179: Research methodology
Exhibit 180: Validation techniques employed for market sizing
Exhibit 181: Information sources
13.5 List of abbreviations
Exhibit 182: List of abbreviations